SUMMARY: The AP reports, “Utah has agreed to a $24 million settlement with Eli Lilly & Co. over claims the drugmaker engaged in off-label marketing of the anti-psychotic drug Zyprexa [olanzapine],” according to Attorney General Mark Shurtleff. The drug is currently “approved for the treatment of schizophrenia and certain types of bipolar disorder,” but “the company’s sales force illegally promoted Zyprexa for uses not approved by the” FDA, including “dementia, Alzheimer’s, agitation, and depression,” he added.

Please see full article below for more inforamtion.

DOCUMENT INFO

RELATED DOCUMENTS BY ROBERT KRAFT